Sarepta Therapeutics, Inc.
Exon skipping oligomer conjugates for muscular dystrophy
Last updated:
Abstract:
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
Status:
Grant
Type:
Utility
Filling date:
14 Dec 2017
Issue date:
12 Jul 2022